J Drugs Dermatol. 2021 Apr 1;20(4):442-449. doi: 10.36849/JDD.2021.5823.
Biologic treatments have taken the forefront in treating moderate-to-severe psoriasis. Although numerous randomized, controlled trials have demonstrated the efficacy of these agents, there is limited data suggesting that clinical trial outcomes are reproducible in real-world patients.
Obtain real-world evidence for the use of biologics that target different segments of the immune system in patients with moderate-to-severe psoriasis.
A retrospective chart review was conducted for 100 patients who initiated biologic therapy and had a follow-up visit within a 4- to 12-month period. Efficacy assessments included body surface area (BSA), Physician’s Global Assessment (PGA) scores, composite BSA×PGA scores, and the National Psoriasis Foundation (NPF) Treat to Target (TTT) goal of ≤1% BSA.
Biologic treatment led to notable reductions in BSA, PGA, and BSA×PGA relative to baseline, with the majority (67.0%) of the population achieving NPF TTT goals at follow-up. Disease improvements were observed in all patients, regardless of baseline body weight, prior experience with biologics, or the specific immune target of the prescribed biologic.
Long-term biologic therapy demonstrated effectiveness in treating patients with moderate-to-severe psoriasis. J Drugs Dermatol. 20(4):442-449. doi:10.36849/JDD.2021.5823Visit the Psoriasis Resource Center for more.
生物制剂在治疗中重度银屑病方面处于领先地位。尽管大量随机对照试验已经证明了这些药物的疗效，但有限的数据表明，临床试验结果在真实世界的患者中是可重现的。
获得针对中重度银屑病患者免疫系统不同靶点的生物制剂的真实世界证据。
对 100 名接受生物治疗并在 4 至 12 个月内进行随访的患者进行回顾性图表审查。疗效评估包括体表面积（BSA）、医生总体评估（PGA）评分、BSAxPGA 评分以及国家银屑病基金会（NPF）达标治疗（TTT）目标≤1%BSA。
与基线相比，生物治疗显著降低了 BSA、PGA 和 BSAxPGA，大多数（67.0%）人群在随访时达到了 NPF TTT 目标。所有患者均观察到疾病改善，无论基线体重、先前使用生物制剂的经验或处方生物制剂的特定免疫靶点如何。
长期生物治疗在治疗中重度银屑病患者方面显示出有效性。皮肤病药物杂志。20（4）：442-449。doi：10.36849/JDD.2021.5823。访问银屑病资源中心了解更多信息。
